Humanigen, Inc. (HGEN): Price and Financial Metrics


Humanigen, Inc. (HGEN): $0.15

0.01 (+4.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HGEN POWR Grades

  • HGEN scores best on the Growth dimension, with a Growth rank ahead of 81.05% of US stocks.
  • HGEN's strongest trending metric is Growth; it's been moving up over the last 43 days.
  • HGEN's current lowest rank is in the Stability metric (where it is better than 6.43% of US stocks).

HGEN Stock Summary

  • The ratio of debt to operating expenses for HUMANIGEN INC is higher than it is for about only 0.51% of US stocks.
  • With a year-over-year growth in debt of -100%, HUMANIGEN INC's debt growth rate surpasses just 0% of about US stocks.
  • The volatility of HUMANIGEN INC's share price is greater than that of 98.78% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to HUMANIGEN INC, a group of peers worth examining would be CNCE, FSR, KZIA, ARAV, and CKPT.
  • Visit HGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.humanigen.com.

HGEN Valuation Summary

  • In comparison to the median Healthcare stock, HGEN's price/sales ratio is 6.25% higher, now standing at 5.1.
  • HGEN's price/sales ratio has moved down 0.1 over the prior 120 months.

Below are key valuation metrics over time for HGEN.

Stock Date P/S P/B P/E EV/EBIT
HGEN 2022-11-25 5.1 -0.3 -0.2 0.1
HGEN 2022-11-23 5.1 -0.3 -0.2 0.1
HGEN 2022-11-22 5.5 -0.3 -0.2 0.1
HGEN 2022-11-21 5.5 -0.3 -0.2 0.1
HGEN 2022-11-18 6.0 -0.4 -0.2 0.0
HGEN 2022-11-17 5.9 -0.4 -0.2 0.0

HGEN Growth Metrics

    Its 4 year cash and equivalents growth rate is now at -95.38%.
  • Its year over year price growth rate is now at -89%.
  • Its 5 year net cashflow from operations growth rate is now at 81.28%.
Over the past 18 months, HGEN's revenue has gone up $2,532,000.

The table below shows HGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.33 -94.387 -108.66
2022-06-30 4.145 -125.08 -151.706
2022-03-31 4.145 -167.663 -192.36
2021-12-31 3.595 -184.045 -236.649
2021-09-30 2.87 -175.481 -235.404
2021-06-30 1.834 -151.022 -199.416

HGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HGEN has a Quality Grade of C, ranking ahead of 29.47% of graded US stocks.
  • HGEN's asset turnover comes in at 0.019 -- ranking 371st of 682 Pharmaceutical Products stocks.
  • ZSAN, ARMP, and AGRX are the stocks whose asset turnover ratios are most correlated with HGEN.

The table below shows HGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.019 1 9.745
2021-03-31 0.011 1 9.024
2020-12-31 0.006 1 6.758
2020-09-30 0.000 NA 5.896
2020-06-30 0.000 NA 3.998
2020-03-31 0.000 NA 1.549

HGEN Price Target

For more insight on analysts targets of HGEN, see our HGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.13 Average Broker Recommendation 1.67 (Moderate Buy)

HGEN Stock Price Chart Interactive Chart >

Price chart for HGEN

HGEN Price/Volume Stats

Current price $0.15 52-week high $5.99
Prev. close $0.14 52-week low $0.13
Day low $0.14 Volume 1,062,900
Day high $0.15 Avg. volume 4,187,642
50-day MA $0.16 Dividend yield N/A
200-day MA $1.32 Market Cap 15.35M

Humanigen, Inc. (HGEN) Company Bio


Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.


HGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

HGEN Latest Social Stream


Loading social stream, please wait...

View Full HGEN Social Stream

Latest HGEN News From Around the Web

Below are the latest news stories about HUMANIGEN INC that investors may wish to consider to help them evaluate HGEN as an investment opportunity.

Humanigen Reports Third Quarter 2022 Financial Results

Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strateg

Yahoo | November 14, 2022

Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference

Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinica

Yahoo | November 10, 2022

Humanigen Announces Retention of SC&H Capital as Financial Advisor

Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affiliate of SC&H Group, to advise Humanigen on exploration of strategic options. SC&H is an investment banking and advisory firm providing merger and acquisition (M&A), financial restructuring and related business a

Yahoo | October 31, 2022

Humanigen Inc. (NASDAQ: HGEN) Stock Forecast: 9.00 USD Or More!

Humanigen Inc. (NASDAQ:HGEN) shares, rose in value on Thursday, 10/27/22, with the stock price up by 1.12% to the previous day’s close as strong demand from buyers drove the stock to $0.14. Actively observing the price movement in the last trading, the stock closed the session at $0.14, falling within a range of $0.1431 and … Humanigen Inc. (NASDAQ: HGEN) Stock Forecast: 9.00 USD Or More! Read More »

Stocks Register | October 28, 2022

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Humanigen, Inc. (HGEN) Investors of Class Action and Last Few Hours to Actively Participate

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN) and certain of its officers on behalf of all persons and entities that purchased, or otherwise acquired Humanigen securities between May 28, 2021, and July 12, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s

Business Wire | October 25, 2022

Read More 'HGEN' Stories Here

HGEN Price Returns

1-mo -0.66%
3-mo -33.30%
6-mo -93.59%
1-year -97.26%
3-year -94.00%
5-year -94.00%
YTD -95.97%
2021 -78.74%
2020 617.95%
2019 -30.36%
2018 73.91%
2017 -89.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6483 seconds.